Progress on the functions and mechanisms of natural products in anti-glioma therapy
- PMID: 40383611
- DOI: 10.1016/S1875-5364(25)60815-6
Progress on the functions and mechanisms of natural products in anti-glioma therapy
Abstract
Glioma, the most prevalent primary tumor of the central nervous system (CNS), is also the most lethal primary malignant tumor. Currently, there are limited chemotherapeutics available for glioma treatment, necessitating further research to identify and develop new chemotherapeutic agents. A significant approach to discovering anti-glioma drugs involves isolating antitumor active ingredients from natural products (NPs) and optimizing their structures. Additionally, targeted drug delivery systems (TDDSs) are employed to enhance drug solubility and stability and overcome the blood-brain barrier (BBB). TDDSs can penetrate deep into the brain, increase drug concentration and retention time in the CNS, and improve the targeting efficiency of NPs, thereby reducing adverse effects and enhancing anti-glioma efficacy. This paper reviews the research progress of anti-glioma activities of NPs, including alkaloids, polyphenols, flavonoids, terpenoids, saponins, quinones, and their synthetic derivatives over the past decade. The review also summarizes anti-glioma mechanisms, such as suppression of related protein expression, regulation of reactive oxygen species (ROS) levels, control of apoptosis signaling pathways, reduction of matrix metalloproteinases (MMPs) expression, blocking of vascular endothelial growth factor (VEGF), and reversal of immunosuppression. Furthermore, the functions and advantages of NP-based TDDSs in anti-glioma therapy are examined. The key information presented in this review will be valuable for the research and development of NP-based anti-glioma drugs and related TDDSs.
Keywords: Anti-glioma; Mechanisms; Natural products; Synthetic derivatives; Targeted drug delivery systems.
Copyright © 2025 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Blood-Brain Barrier- and Blood-Brain Tumor Barrier-Penetrating Peptide-Derived Targeted Therapeutics for Glioma and Malignant Tumor Brain Metastases.ACS Appl Mater Interfaces. 2019 Nov 13;11(45):41889-41897. doi: 10.1021/acsami.9b14046. Epub 2019 Oct 29. ACS Appl Mater Interfaces. 2019. PMID: 31615203
-
Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma.Biomaterials. 2011 Jun;32(18):4293-305. doi: 10.1016/j.biomaterials.2011.02.044. Epub 2011 Mar 21. Biomaterials. 2011. PMID: 21427009
-
Targeted delivery strategy of indocyanine green-mitoxantrone loaded liposomes co-modified with BTP-7 and BR2 for the treatment of glioma.Pharm Dev Technol. 2025 Jan;30(1):90-100. doi: 10.1080/10837450.2024.2448619. Epub 2025 Jan 8. Pharm Dev Technol. 2025. PMID: 39745268
-
The blood-brain/tumor barriers: challenges and chances for malignant gliomas targeted drug delivery.Curr Pharm Biotechnol. 2012 Sep;13(12):2380-7. doi: 10.2174/138920112803341798. Curr Pharm Biotechnol. 2012. PMID: 23016643 Review.
-
Natural polymeric nanocarriers in malignant glioma drug delivery and targeting.J Drug Target. 2021 Nov;29(9):960-973. doi: 10.1080/1061186X.2021.1904250. Epub 2021 Sep 23. J Drug Target. 2021. PMID: 33745392 Review.
Cited by
-
Pyrogallol induces apoptosis, oxidative stress and cell cycle arrest in C6 glioma cells: a potential therapeutic agent.Med Oncol. 2025 Jun 27;42(8):290. doi: 10.1007/s12032-025-02835-w. Med Oncol. 2025. PMID: 40576869
-
Ferroptosis as a Therapeutic Avenue in Triple-Negative Breast Cancer: Mechanistic Insights and Prognostic Potential.Biomedicines. 2025 Aug 21;13(8):2037. doi: 10.3390/biomedicines13082037. Biomedicines. 2025. PMID: 40868287 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous